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Abstract 
Background and Aims 
The obesity epidemic has led to increased use of Roux-en-Y gastric bypass (RYGB). These 
patients have an increased incidence of pancreaticobiliary diseases yet standard ERCP is not 
possible due to surgically altered gastroduodenal anatomy. Laparoscopic-ERCP (LA-ERCP) has 
been proposed as an option but supporting data are derived from single center small case-series.  
Therefore, we conducted a large multicenter study to evaluate the feasibility, safety, and 
outcomes of LA-ERCP. 
 
Methods 
This is retrospective cohort study of adult patients with RYGB who underwent LA-ERCP in 34 
centers.  Data on demographics, indications, procedure success, and adverse events were 
collected.  Procedure success was defined when all of the following were achieved: reaching the 
papilla, cannulating the desired duct and providing endoscopic therapy as clinically indicated.  
 
Results 
A total of 579 patients (median age 51, 84% women) were included.  Indication for LA-ERCP 
was biliary in 89%, pancreatic in 8%, and both in 3%.  Procedure success was achieved in 98%.  
Median total procedure time was 152 minutes (IQR 109-210) with median ERCP time 40 
minutes (IQR 28-56).  Median hospital stay was 2 days (IQR 1-3).  Adverse events were 18% 
(laparoscopy-related 10%, ERCP-related 7%, both 1%) with the clear majority (92%) classified 
as mild/moderate whereas 8% were severe and 1 death occurred.   
 
Conclusion 
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Our large multicenter study indicates that LA-ERCP in patients with RYGB is feasible with a 
high procedure success rate comparable with that of standard ERCP in patients with normal 
anatomy.  ERCP-related adverse events rate is comparable with conventional ERCP, but the 
overall adverse event rate was higher due to the added laparoscopy-related events. 
 
 
Background  
The current obesity epidemic has consequently led to an increase in bariatric surgery, with more 
than 100,000 procedures per year being performed in the United States alone 1.  In recent years, 
the most common bariatric surgery has been and continues to be Roux-en-Y gastric bypass 
(RYGB) 1,2. This operation excludes most of the stomach (ie, remnant stomach) and all of the 
duodenum making conventional duodenoscopy and per-oral ERCP impossible.  Importantly, 
ERCP is commonly indicated in RYGB patients due to an increased risk of choledocholithiasis 
and gallstone pancreatitis especially in the setting of rapid weight loss after bariatric surgery 3,4.  
Furthermore, several reports have shown increased rate of pancreaticobiliary malignancies in 
obese patients 5,6.  
Various alternative ERCP approaches for patients with RYGB have been described.  Per-oral 
deep enteroscopy techniques such as single-balloon, double-balloon and spiral enteroscopy are 
minimally invasive but therapeutic success is far lower compared with standard ERCP.  This 
inferiority is due to the inability to reach the papilla secondary to the surgically altered 
gastroduodenal anatomy, failure to cannulate the desired duct, or failure to provide therapy due 
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to the change of orientation of the papilla, difficult endoscope position, use of forward optics, 
lack of elevator, small therapeutic channel and/or limited availability of devices 7-13.   
Percutaneous access to the gastric remnant by interventional radiology has been described, but 
has not gained wide acceptance because it is impractical for urgent cases due to the requirement 
of serial dilation and track maturation 14-16.  This is further hindered by the inconvenience of 
needing a gastrostomy tube (G-tube) and the technical difficulties related to the inability to 
distend the stomach remnant with air 6,17.  EUS-guided transgastric ERCP is another innovative 
approach 18,19.  However, this methodology has several cited limitations most prominently is the 
potential for creating a permanent gastro-gastric fistula that compromises the integrity of the 
RYGB and the need for 2 stage procedure 20-22. 
Laparoscopy-assisted ERCP (LA-ERCP) is accomplished by placing trocar in the remnant 
stomach under laparoscopic guidance followed by insertion of the conventional duodenoscope 
through the trocar to reach the ampulla of Vater.  ERCP is then carried out in a standard fashion. 
The main appeal of LA-ERCP is that it is a single-stage procedure and affords the use of 
standard ERCP equipment including doudenoscope and accessories.  This anticipates a very high 
procedural success, similar to patients with normal upper GI tract anatomy.  LA-ERCP was first 
described in 2002 and since then, only a few small single-center case series have been published 
showing high success rates and low adverse events rates 6,7,23-25.  Despite these early encouraging 
results, the role of LA-ERCP has not been well defined due to a lack of high quality data.  
Therefore, the aim of this study was to evaluate a large multicenter cohort to assess the 
feasibility, safety and outcomes of LA-ERCP in patients with RYGB. 
Methods 
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This is a retrospective multicenter cohort study that included adult patients with RYGB who 
underwent LA-ERCP between 2005 and 2016.  The study was approved by the institutional 
review board (IRB) of each of the participating centers, with the University of Florida serving as 
the central coordinating center.  All authors had access to the study data and reviewed and 
approved the final manuscript. 
Procedure 
Procedure informed consents for both ERCP and Laparoscopy were obtained from all patients.  
All procedures were performed in the operating room or designated sterile endoscopy room by 
both a laparoscopy and endoscopy teams with the patient in supine position under general 
anesthesia.  Percutaneous access with trocar to the remnant stomach was established 
laparoscopically.  Therapeutic duodenoscope was subsequently inserted through the indwelling 
trocar into the remnant stomach and advanced into the duodenum.  ERCP was then carried out in 
a standard fashion using a conventional duodenoscope and accessories.  The gastrostomy and the 
percutaneous tracts were closed surgically at the end of the procedure or a G-tube is left in place 
in cases where ERCP might be needed again in the future.  All patients were inpatients or were 
admitted for observation postoperatively. 
Data collection 
A standardized data entry form was distributed through secured email across all the centers to 
collect information on baseline characteristics, intra-procedural and follow-up data. Baseline 
characteristics included patient demographics, American Society of Anesthesiologists (ASA) 
class, year and type of RYGB surgery (laparoscopic versus open), cholecystectomy status 
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(before LA-ERCP, at the time of LA-ERCP, after the LA-ERCP), prior failed attempts at 
pancreatico-biliary interventions, indication and type of LA-ERCP (biliary, pancreatic or both). 
Procedure-related data included the use of peri-operative antibiotics, total procedure time, ERCP 
time, the types of ERCP therapeutic interventions (biliary sphincterotomy, dilation of the papilla, 
dilation of stricture, biliary or pancreatic stent placement or extraction, stone/sludge removal), 
need for conversion from laparoscopic to open surgery, G-tube placement, and length of hospital 
stay (LOS).  
Definitions 
Procedure success was defined when all of the following were accomplished: reaching the 
ampulla of Vater, cannulation of the desired duct, and performing the desired therapeutic 
maneuvers as clinically indicated. Total procedure time was measured from the initial surgical 
incision to final surgical closure.  ERCP time was measured from the scope insertion in the 
trocar to the scope withdrawal.   
Adverse events were classified to either ERCP-related (pancreatitis, cholangitis, sphincterotomy-
related perforation, post-sphincterotomy bleeding, stent migration, or others), or laparoscopy-
related (bleeding, gastric remnant site entry leak, gastric tube site infection, perforation, 
cardiovascular, other infection, or others).  Severity of adverse events was classified using the 
American Society for Gastrointestinal Endoscopy lexicon as mild, moderate, severe, and death 
26
. 
Statistical analysis 
Data were analyzed using SPSS version 18.0 software (SSPS Inc, Chicago, Ill).  Mean, median 
and interquartile ranges (IQR) were calculated.  Categorical data were analyzed using the Fisher 
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exact and Chi square testing and continuous data were analyzed using t testing for normally 
distributed variables and Mann–Whitney U test for non-normally distributed variables.  
Results 
Thirty-four centers participated in this study (31 from the United States, 2 from Brazil, and 1 
from Canada, Table 1).  A total of 579 patients with RYGB (84% women) with median age of 51 
(interquartile range (IQR) 43-61) underwent LA-ERCP during the study period (2005-2016) 
(Table 2).  The number of procedures performed per year increased noticeably after 2011 
reflecting increased adoption of this approach (Figure 1). 
Indications for LA-ERCP are outlined in Table 2.  Main indications for procedures were: biliary 
in 89%, pancreatic in 8% and both biliary and pancreatic in 3% of the cases.  Approximately half 
(47%) of all biliary interventions were due to choledocholithiasis whereas acute pancreatitis 
(93%) was the most common indication for pancreatic intervention.  The most common 
therapeutic interventions were biliary sphincterotomy (96%), stone extraction (44%), and 
pancreatic stent placement (15%), (Table 3).  Eleven patients (26%) among those with pancreatic 
pre-operative indication had stone extraction.  Concomitant laparoscopic cholecystectomy was 
performed in 21% of the cases and gastric tube was left in place in 17% of the cases for possible 
subsequent intervention(s).  
Overall procedure success was achieved in 98%.  The papilla was successful reached in 99% and 
cannulating the desired duct in 98% of the cases (bile duct cannulation 99%, pancreatic duct 
cannulation 91%).  Success rate in performing the desired intervention was 98% (biliary 99%, 
pancreatic 89%).  Median total procedure time (laparoscopy + ERCP) was 152 minutes (IQR 
109-210 minutes) whereas median ERCP time was 40 minutes (IQR 28-56) minutes.  Median 
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total procedure time was significantly longer for patient with history of open versus laparoscopic 
RYGB (181 versus 147 minutes, p=0.009).  Median LOS was 2 (IQR 1-3) days. 
Adverse events were reported in 106 out of 579 (18%) patients.  Laparoscopy-related adverse 
events were reported in 10% whereas ERCP-related adverse events were reported in 7% of the 
patients.  One percent of the patients had adverse events related to both laparoscopy and ERCP.  
The most common laparoscopy associated adverse event was postoperative infections in 24 out 
of 579 (4.1%), whereas the most common ERCP-related adverse event was acute pancreatitis in 
42 out of 579 (7.4%), (Table 4).  The rate of pancreatitis varied by the LA-ERCP main 
indication, among those who had the procedure for biliary indications was 7%.  Compared with 
the rate among those with pancreatic and both (biliary and pancreatic) indications, which was 
11% and 13%, respectively (p=0.3).  Regarding the severity of these events, 60% were classified 
as mild and 31% as moderate whereas 8% were classified as severe and one death was reported.  
In 5% of the cases ERCP was carried out after conversion to open laparotomy to gain access to 
the remnant stomach. 
We explored the factors associated with laparoscopic versus ERCP-related events by series of 
univariate analysis as presented in Table 5.  Longer duration since RYGB showed a trend 
towards higher laparoscopy-related events (<3 years had 8%, 3-6 years had 10%, 6-9 years had 
10%, and those with >10 years since RYGB had 16%, p=0.516).  Conversion to open laparotomy 
was associated with significant increase in the risk of laparoscopy-related events (24% versus 
10%, p=0.045).  Leaving a G-tube in place at the end of the procedure was also significantly 
associate with increased risk of adverse events (17% versus 9%, p=0.036).  These factors (years 
since RYGB, conversion to open, and leaving G-tube) did not affect the ERCP-related adverse 
events. 
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Most of the patients (85%) received peri-operative antibiotics.  Antibiotics use was associated 
with a numerically higher overall adverse events rate (19% versus 13%, p = 0.198), a 
numerically higher rate of any infectious adverse events (6.2% versus 3.4%, p = 0.451), and a 
numerically higher rate of G tube site infection (1.4 % versus 0%, p = 0.603).  
Discussion  
The feasibility of LA-ERCP has been reported from a few single-center case series, with 
reported success rate ranging from 80% to 100% and adverse events rate ranging from 0% to 
30% 6,7,23-25,27-32.  These reports are limited by small sample size and heterogeneous definitions of 
procedure success and adverse events.  In our large multicenter study, LA-ERCP in patients with 
RYGB was highly successful with success rates comparable to standard ERCP in patients with 
normal upper GI tract anatomy 33.  In our study, the overall success rates in reaching the papilla, 
cannulating the desired duct and performing the indicated therapeutic intervention was 98%.  
Furthermore, we also demonstrated that LA-ERCP is feasible and efficient.  Our total procedure 
time (laparoscopy + ERCP) was 152 minutes with median length of hospital stay of 2 days.   
In our series, ERCP-related adverse events rate appear comparable with conventional ERCP, 
although the overall rate of adverse events was higher due to the addition of those attributed to 
laparoscopy33.  Importantly, the clear majority (92%) of the reported adverse events were 
classified as mild to moderate.  Nevertheless, serious adverse events were seen including viscus 
perforation in 5/579 (0.8%) cases.  Two patients had sphincterotomy-related duodenal 
perforations, whereas the rest were laparoscopy-related (2 colonic and 1 gastric remnant 
perforation [trocar perforated the posterior stomach wall]).  In one of the perforation cases, 
multi-organ failure occurred and the patient died after a prolonged hospitalization.   
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Placing an indwelling G-tube and conversion to open laparotomy were factors significantly 
associated with higher laparoscopy-related adverse events.  Patients who had G tube left had 
higher overall laparoscopy associated adverse events (17% versus 9%, p =0.03).  This was 
attributed to G tube site infection (6%), gastric entry-site leak (4%), and all-causes laparoscopy-
associated bleeding (7%).  Of note, all patients who had G tube site infection did receive peri-
operative antibiotics as part of their care.  Based on these data, it seems reasonable to avoid G-
tube insertion unless a repeat procedure is definitely indicated, (Table 5).   
Most of the patients included in our series (85%) received periprocedural antibiotics.  There was 
no statistically significant difference in infection rate between those who received antibiotics 
versus those who did not.  Nevertheless, we cannot exclude any difference based on our findings 
due to the very low rate of infections and low statistical power to answer this question.  
Therefore, our data cannot provide definitive guidance for or against the use of perioperative 
antibiotics.   
Our findings are comparable with the recently published systematic review of 26 studies by 
Banerjee et al that included 509 laparoscopic and open trans-gastric ERCP cases 34. The success 
rate in reaching the papilla, cannulation, and performing therapeutic intervention were 98.9%, 
98.5%, and 98.5%, respectively. Adverse events were reported in 14% of cases, with lower G 
tube site infection (3.7%) and laparoscopy-associated bleeding (0.9%), and no reported death 
compared with our findings 34.  
It is noteworthy that EUS-guided transgastric ERCP  is currently an evolving and promising 
approach that involves deploying lumen-apposing metal stent (LAMS) through the newly formed 
gastro-gastric fistula18. Then the intended ERCP could be performed by passing the endoscope 
into the remnant stomach through the LAMS 18-20.  This approach can potentially offer great 
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advantages including the lack of need for surgical team, minimal invasiveness, and the higher 
success rate and shorter operative time compared with enteroscopy assisted ERCP.  However, 
this methodology has several cited limitations most prominently the potential for creating a 
permanent fistula that compromises the integrity of the RYGB 20-22, high LAMS dislodgement 
rate (19%), and the need for multiple sessions in two-thirds of the patients to allow time for track 
maturation 35.  Nonetheless, this is a promising approach and direct comparison with LA-ERCP 
is warranted in future research. 
The main strengths of our study include (1) large sample size. (2) Diverse patient population 
from many centers across the United Sates, Brazil, and Canada.  This should improve our 
findings’ external validity by providing more generalizable estimates of success and adverse 
events rates across many levels of endoscopists’ and surgeons’ experiences.  These estimates can 
serve as reference to physicians when counseling patients.  (3) Standardization of definitions for 
the outcomes and adverse events.  (4) Reporting on all cases done in particular institution thus 
hopefully decreasing the possibility of selection bias.  (5) Our findings are congruent with the 
findings of earlier smaller studies 6,7,23-25,27-32.  
Laparoscopy-assisted ERCP has the advantage of using standard side-viewing duodenoscope and 
the standard ERCP accessories, thus increasing the cannulation and therapeutic intervention 
success rates.   Furthermore, because LA-ERCP is done in conjunction with surgeons in the 
operating room, concomitant cholecystectomy can be performed if clinically indicated.  In our 
population, concomitant cholecystectomy was performed in 20%.  Saleem et al25 reported 
performing concomitant cholecystectomy in 20% of the patients.   Additionally, laparoscopic 
approach allows the diagnosis and treatment of internal hernias (reported in 20%-40%) and 
adhesions (in 20%) of the LA-ERCP procedures 23,25.  
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Nonetheless, there are several challenging aspects of LA-ERCP that must be addressed before 
adoption of this procedure by a medical center.  The center must have expertise in bariatric 
surgery as well as advanced endoscopy.  Secondly, maintaining sterility, the lay out of the OR, 
and its equipment are different from what the endoscopy team is accustomed to in the usual 
endoscopy suites 25.  Thus, a special protocol has to be devised and taught to the endoscopy team 
25
.  In addition, a great deal of schedule coordination is required to ensure that the endoscopist 
and the surgeon along with their teams are present in the OR at the same time to avoid delays25.  
At the University of Florida and The Cleveland Clinic, the LA-ERCPs are typically scheduled as 
the first cases of the day to ensure that the 2 teams are available and there would be no 
interference with the rest of the OR and endoscopy schedules.  
Our study has the typical limitations inherent to retrospective design related to potential for 
patient selection bias, and measurement bias particularly the under-reporting of adverse events.  
We anticipate that underreporting was minimized in our cohort because all of our patients were 
inpatients or were admitted to the hospital after surgery, making detection and reporting of 
adverse events more likely.  In addition, for clarity of reporting we divided adverse events into 
ERCP or laparoscopy-related categories.  Such a distinction may be straightforward for most 
adverse events such as post-ERCP pancreatitis but could be arbitrary for others such as 
cardiovascular compromise.  Nevertheless, the reported overall adverse event rate should provide 
an accurate estimate to use as a guide for physicians and patients.  
Our large multicenter study indicates that LA-ERCP in patients with RYGB is highly successful, 
with success rates comparable to standard ERCP in patients with normal upper GI tract anatomy.  
ERCP-related adverse event rates also appear comparable with those expected of conventional 
ERCP, but the overall adverse events rate was higher due to the addition of laparoscopy- related 
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events.  Although the majority of such events were mild to moderate, rare severe adverse events 
are possible.  Given the exceptionally high technical success rate and acceptable safety profile, 
LA-ERCP can be considered as one of the first-line approaches in patients with RYGB who 
require ERCP.  Comparative studies with alternative procedures such as EUS-guided gastro-
gastrostomy may further refine our approach in this very challenging patient population.  
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Table 1: Participating Centers  
Center name City State Country Patients 
Cirurgia Digestiva e Obesidade Salvador Bahia Brazil 26 
Cleveland Clinic Cleveland OH USA 52 
Dartmouth-Hitchcock Medical Center Lebanon NH USA 14 
Duke University Durham  NC  USA 28 
Fox Chase Cancer Center Philadelphia PA USA 6 
Geisinger Medical Center Danville  PA USA 49 
Indiana University Indianapolis  IN USA 24 
Mayo Clinic Scottsdale Scottsdale  AZ  USA 7 
Medical College of Wisconsin Milwaukee WI USA 11 
Medical University of South Carolina Charleston  SC USA 12 
Methodist Dallas Medical Center Dallas TX USA 23 
Northwestern University Chicago IL USA 6 
Oregon Health & Science University Portland OR USA 17 
Poudre Valley Hospital Fort Collins CO USA 10 
Stony Brook University School of Medicine Stony Brook NY USA 5 
The University of Ottawa Ottawa ON CA 3 
Thomas Jefferson University Philadelphia PA USA 8 
University Hospitals Case Medical Center Cleveland OH USA 8 
University of California Los Angeles (UCLA) Santa Monica CA USA 16 
University of Colorado, Denver Denver CO USA 36 
University of Florida Gainesville FL USA 20 
University of Maryland School of Medicine Baltimore MD USA 30 
University of Massachusetts Worcester MA USA 28 
University of Michigan Ann Arbor MI USA 14 
University of Rochester Medical Center  Rochester NY USA 8 
University of São Paulo Medical School & 
Gastro-Obeso-Center Institute 
São Paulo São 
Paulo 
Brazil 14 
University of South Alabama Mobile AL USA 2 
University of South Florida Tampa FL USA 8 
University of Virginia Charlottesville VA USA 10 
University of Washington Seattle WA USA 17 
Virginia Mason Medical Center Seattle WA USA 28 
Virginia Tech Carilion School of Medicine Roanoke VA USA 9 
Wake Forest Baptist Medical Center Winston Salem NC  USA 16 
Yale School of Medicine New Haven CT USA 14 
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Table 2: Demographics and other clinical factors of the included population 
  No. % 
Age quartile <42 144 25% 
42-51 148 26% 
52-61 157 27% 
>61 130 22% 
Gender Female 488 84% 
Male 91 16% 
ASA class  1 4 1% 
2 242 44% 
3 291 53% 
4 14 3% 
Type bariatric surgery  Laparoscopic Roux-en-Y gastric bypass 340 68% 
Open Roux-en-Y gastric bypass 160 32% 
Years since RYGB, quartiles <3  146 30% 
3-6 106 22% 
7-10 125 25% 
>10 116 24% 
Cholecystectomy Before ERCP 423 78% 
At the time of ERCP 114 21% 
After ERCP 6 1% 
Prior failed attempts of 
pancreaticobiliary interventions 
No prior attempt reported 438 76% 
Enteroscopy ERCP 109 19% 
PTC 26 4% 
Laparoscopic bile duct exploration 5 1% 
Open bile duct exploration 1 0% 
Main Indication  Biliary 518 89% 
Pancreatic 45 8% 
Both 16 3% 
Biliary indication Biliary stone 254 47% 
Suspected papillary stenosis 102 19% 
Dilated duct 75 14% 
Abnormal LFTs 46 9% 
Bile duct stricture 20 4% 
Post cholecystectomy pain  10 2% 
Others/abdominal pain 9 2% 
Bile leak 7 1% 
Ampullary lesion 7 1% 
Biliary stent removal 3 1% 
Abnormal intraoperative cholangiogram  2 0% 
Pancreatic Indications Pancreatitis 56 93% 
Dilated pancreatic duct 3 5% 
Pancreatic duct stone 1 2% 
Peri-operative antibiotics No 89 15% 
Yes 489 85% 
LA-ERCP goal Therapeutic 574 99% 
Diagnostic 5 1% 
Notes, LA-ERCP: Laparoscopy assisted ERCP.  
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Table 3: Interventions performed during LA-ERCP.  
No. % 
Biliary sphincterotomy 550 96% 
Stone/sludge/cast extraction 253 44% 
Pancreatic duct stent placement 88 15% 
Dilation of the papilla 82 14% 
Dilation of the ampullary orifice with large balloon (≥ 12 mm) 48 8% 
Plastic biliary stent placement 32 6% 
Pancreatic stent extraction 10 2% 
Biliary stent extraction 20 3% 
Dilation of a stricture 17 3% 
Metal biliary stent placement 6 1% 
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Table 4: Adverse events 
Laparoscopy related 
Other postoperative infections 24/579 4.1% 
Laparoscopy-related bleeding 10/579 1.7% 
Gastric site leak 7/579 1.2% 
Gastric tube site infection 7/579 1.2% 
Postoperative respiratory adverse events 6/579 1.0% 
Postoperative cardiovascular adverse events 4/579 0.7% 
Laparoscopy related perforation 3/579 0.5% 
Other laparoscopic related adverse event 11/579 1.9% 
ERCP-related 
Pancreatitis 43/579 7.4% 
Cholangitis 6/579 1.0% 
ERCP-related bleeding 3/579 0.5% 
ERCP-related perforation 2/579 0.3% 
Stent migration 1/579 0.2% 
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Table 5: Subgroup analyses of adverse events  
  
Adverse Events   
Non 
ERCP- 
Related 
Laparoscopy- 
Related 
No. % No. % No. % 
P 
value  
Age quartile <42 121 86% 11 8% 9 6% 0.448 
42-51 122 82% 13 9% 13 9% 
52-61 124 81% 10 7% 19 12% 
>61 107 83% 6 5% 16 12% 
Gender Female 395 82% 37 8% 50 10% 0.237 
Male 79 89% 3 3% 7 8% 
ASA class  1 4 100% 0 0% 0 0% 0.225 
2 198 83% 23 10% 18 8% 
3 235 82% 15 5% 37 13% 
4 11 79% 1 7% 2 14% 
Type Bariatric 
Surgery  
Lap RYGB 285 85% 20 6% 30 9% 0.180 
Open RYGB 123 78% 14 9% 20 13% 
Cholecystectomy Before the ERCP 341 82% 34 8% 41 10% 0.135 
At the time of ERCP 99 88% 2 2% 12 11% 
After ERCP 6 100% 0 0% 0 0% 
Main Indication  Biliary 428 84% 34 7% 50 10% 0.029 
Pancreatic 36 84% 5 12% 2 5% 
Both 10 63% 1 6% 5 31% 
Years since RYGB, 
quartiles 
<3 123 85% 10 7% 11 8% 0.516 
3-6 86 82% 8 8% 11 10% 
6-10 102 82% 9 7% 13 10% 
>10 85 75% 10 9% 18 16% 
Conversion to open No 432 83% 36 7% 50 10% 0.045 
Yes 20 69% 2 7% 7 24% 
G tube left in place No 384 84% 30 7% 41 9% 0.036 
Yes 68 74% 8 9% 16 17% 
Note: patients who had both ERCP and laparoscopy related adverse events were excluded from this 
analysis (8 patients).  P values are derived from comparing the distribution of adverse event across all 
the groups within the same variable.  
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LA-ERCP  = Laparoscopy-Assisted Endoscopic Retrograde Cholangiopancreatography  
RYGB  = Patients with Roux-en-Y Gastric Bypass 
G-tube  = gastrostomy tube  
IRB = institutional review board  
LOS = length of hospital stay  
IQR = interquartile ranges  
 
 
